Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis

Journal of Cellular Physiology

Volumn 155, Issue 3, 1993, Pages 568-578

  Blei, Francine ^a   Wilson, E Lynette ^a   Mignatti, Paolo ^a   Rifkin, Daniel B ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b New York University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINAE; TRIXIS; ANIMALIA; BOS TAURUS;

BASIC FIBROBLAST GROWTH FACTOR; DEXAMETHASONE; HEPARIN; HYDROCORTISONE; HYDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; AORTA; ARTICLE; CATTLE; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

17-HYDROXYPROGESTERONE; ANIMAL; AORTA; CATTLE; CELLS, CULTURED; DEXAMETHASONE; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HYDROCORTISONE; HYDROXYPROGESTERONES; MEDROXYPROGESTERONE 17-ACETATE; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; STEROIDS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; URINARY PLASMINOGEN ACTIVATOR;

EID: 0027190788     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.1041550315     Document Type: Article

References (60)

1. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen
2. Hormonal regulation of extracellular plasminogen activators and Mr 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies
3. The receptor‐binding sequence of urokinase
4. Medroxyprogesterone acetate, an anti‐cancer and anti‐angiogenic steroid, inhibits plasminogen activator in bovine endothelial cells
5. Migration and proliferation of endothelial cells in pre‐formed and newly formed blood vessels during tumor angiogenesis
6. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment
7. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1
8. Plasminogen activators and cancer
9. Plasminogen purification from human plasma by affinity chromatography
10. Reverse fibrin autoradiography: A method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate polyacrylamide gel electrophoresis
11. The primary plasminogen activator inhibitors in endothelial cells, platelets, and plasma are immunologically related
12. Angiogenesis
13. Angiogenesis
14. Angiogenic factors
15. Long‐term culture of capillary endothelial cells
16. Control of angiogenesis with synthetic heparin substitutes
17. Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors
18. 3H mouse mammary tumor by medroxyprogesterone acetate
19. The synovial microvasculature in rheumatoid arthritis and osteoarthritis
20. A study of proteases and protease‐inhibitor complexes in biological fluids
21. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone
22. Plasminogen activator and collagenase production by cultured capillary endothelial cells
23. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro
24. Mechanochemical switching between growth and differentiation during fibroblast growth factor‐stimulated angiogenesis in vitro: Role of extracellular matrix
25. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution
26. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth
27. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial
28. Shark cartilage contains inhibitors of tumor angiogenesis
29. Cultured bovine endothelial cells produce both urokinase and tissue‐type plasminogen activators
30. Vitreous: An inhibitor of retinal extract‐induced neovascularization
31. Inhibition of angiogenesis by recombinant human platelet factor‐4 and related peptides
32. Role of degradative enzymes in wound healing
33. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor‐induced proteinases
34. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor
35. Urokinase‐type and tissue‐type plasminogen activators have different distributions in cultured bovine capillary endothelial cells
36. Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis
37. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration
38. Identification of an inhibitor of neovascularization from cartilage
39. The microvascular extracellular matrix: Developmental changes during angiogenesis in the aortic ring plasma clot model
40. Angiogenic activity of rat mammary carci‐nomas induced by 7,12‐dimethyl‐benz(a)anthracene and its inhibition by medroxyprogesterone acetate: Possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition
41. Powerful antiangiogenic activity of Herbimycin A
42. Transforming growth factor‐beta 1 modulates basic fibro‐blast growth factor‐induced proteolytic and angiogenic properties of endothelial cells in vitro
43. Plasminogen activator inhibitor‐1 is induced in migrating endothelial cells
44. The regulatory region of the human plasminogen activator inhibitor type‐1 (PAI‐1) gene
45. Cell‐associated plasminogen activation: Regulation and physiological functions
46. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells
47. Selection and characterization of bovine aortic endothelial cells
48. Inhibition of angiogenesis by interferons: Effects on tumor‐ and lymphocyte‐induced vascular reponses
49. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus
50. Interaction of heparin with human basic fibroblast growth factor (FGF): Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan
51. Angiogenesis inhibition by minocycline
52. Protamine is an inhibitor of angio‐genesis
53. Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids
54. Inhibition of in vitro angiogenesis by lymphotoxin and interferon‐gamma
55. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter
56. Endothelial cell‐derived basic fibroblast growth factor: Synthesis and deposition into suben‐dothelial extracellular matrix
57. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator
58. A proenzyme form of urokinase